Vimarsana
Biggest News Aggregation in the World

Brian Koffman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Brian Koffman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Brian Koffman Today - Breaking & Trending Today

CDC Could Cut COVID Isolation Time: What It Could Mean - Vimarsana News

CDC Could Cut COVID Isolation Time: What It Could Mean

The agency appears to be walking a fine line between reducing COVID transmission, including the JN.1 variant, and the reality that many people struggle to forgo work or school for days at a time.

Source: webmd.com
Beyond chemotherapy: Navigating the promise and perils of CAR-T therapy in pediatric cancer - Vimarsana News

Beyond chemotherapy: Navigating the promise and perils of CAR-T therapy in pediatric cancer

Upon hearing the phrase ‘cancer treatment’, the first word that can typically spring to mind is chemotherapy – a primary therapy which uses powerful chemicals to destroy rapidly growing cancer cells in the body.

CLL Society's Koffman Says ASH 2023 Offered "Evolutionary" Changes - Vimarsana News

CLL Society's Koffman Says ASH 2023 Offered "Evolutionary" Changes

This interview will appear in the January 2024 issue of Evidence-Based Oncology.™ Each year, our January issue features a recap of proceedings from the American Society of Hematology Meeting and Exposition.

Source: ajmc.com
The Emotional Impact of a Cancer Diagnosis: How to Cope and Find Hope - Vimarsana News

The Emotional Impact of a Cancer Diagnosis: How to Cope and Find Hope

A cancer diagnosis brings about emotions such as fear, denial, anger, and depression. Finding early support and learning coping strategies are important for survival.

FDA Approves Pirtobrutinib For Treatment of Adult Patients With CLL, SLL - Vimarsana News

FDA Approves Pirtobrutinib For Treatment of Adult Patients With CLL, SLL

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.